id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-344486-iu5flbcl	Chiotos, Kathleen	Multicenter interim guidance on use of antivirals for children with COVID-19/SARS-CoV-2	2020-09-12		.txt	text/plain	8595	416	37	In the few months since this initial publication, new evidence has emerged demonstrating the efficacy of the antiviral medication remdesivir in shortening time to clinical recovery in adults with COVID-19, while several other studies have shown ineffectiveness of hydroxychloroquine and lopinavir-ritonavir (4) (5) (6) (7) (8) . Further, additional observational studies have provided insight into the clinical epidemiology of COVID-19 in children, demonstrating that while most young patients experience mild illness, a small proportion develop severe illness associated with adverse clinical outcomes, including need for pediatric intensive care unit (PICU) admission and mortality (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) . Nevertheless, the panel recognizes that pediatric clinicians are likely to consider comorbidities when weighing the risks and benefits of antiviral therapy on a case-bycase basis, and in making these decisions may consider: 1) the available, albeit limited, pediatric COVID-19 literature; 2) risk factors associated with severe COVID-19 in adults; and 3) pre-existing medical conditions in children associated with worse clinical outcomes for other viral infections.	./cache/cord-344486-iu5flbcl.txt	./txt/cord-344486-iu5flbcl.txt